Related Experiment Video
Updated: Jun 22, 2025
08:20
Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure
Published on: January 18, 2021
4.0K
Rivastigmine for treatment-refractory posttraumatic stress disorder: a systematic review
P A Maguire1,2, T Bastiampillai2,3,4, S Allison2,3
1Academic Unit of Psychiatry and Addiction Medicine, Australian National University School of Medicine and Psychology, Canberra Hospital, Canberra, Australia.
Summary
This review found no strong evidence that rivastigmine augmentation effectively treats treatment-refractory posttraumatic stress disorder (PTSD). More rigorous research is needed to confirm any potential benefits for PTSD patients.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Posttraumatic stress disorder (PTSD) is a debilitating condition often requiring multifaceted treatment approaches.
- Treatment-refractory PTSD presents significant challenges, necessitating exploration of novel therapeutic strategies.
- Augmentation therapies are investigated to enhance outcomes in patients with persistent PTSD symptoms.
Conclusions:
- Current evidence from methodologically robust studies does not support the efficacy of add-on rivastigmine for treating refractory PTSD.
- The existing studies exhibit significant limitations, including small sample sizes, weak designs, and inadequate outcome measures.
- Further high-quality research is warranted to definitively assess the clinical utility of rivastigmine in managing treatment-resistant PTSD.
